Proposed Data Collection Submitted for Public Comment and Recommendations, 85887-85888 [2023-27081]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 236 / Monday, December 11, 2023 / Notices
requirement accommodates required
updates to FBO reporting systems.
Commenters also recommended
retaining the option for FBOs to file the
FR Y–7Q on a fiscal year basis.
Commenters stated that FBOs that
follow a non-calendar fiscal year base
their home country reporting
requirements, internal and external
financial reporting, and management
information systems around the 90-day
filing deadline for the FR Y–7Q.
In response to the comments received,
the Board will move forward with a
modified approach so that only the
following three items that capture U.S.
assets would be required to be filed on
a calendar period basis: Line item 6(a)—
Total combined U.S. assets net of
intercompany balances and
transactions; Line item 6(b)—Total
combined U.S. assets net of
intercompany balances and
transactions, based on a quarterly
average; and Line item 7—Total onbranch assets. The remaining line items
on the FRY–7Q will continue to be
collected with fiscal filing as an option.
The Board has also decided to retain
line item 8, as-of financial date, in Part
1A and line item 6, as-of financial date,
in Part 2, in order to continue the use
of the fiscal filing option, which will
only apply to non-U.S. asset line items.
FR Y–7Q respondents that are required
to file the FR Y–15 would have already
submitted total combined U.S. assets net
of intercompany balances and
transactions, given that the FR Y–15 is
due 50 calendar days after March 31,
June 30 and September 30, and 65 days
after December 31. Individual
respondents that believe the information
they are required to submit under the
FR Y–7Q is nonpublic commercial or
financial information, which is both
customarily and treated as private by
the respondent, may request
confidential treatment of such
information under exemption 4 of the
FOIA.
Finally, commenters expressed
concern about shortening the filing
deadline for the FR Y–7Q because firms
may need more than 30 days to provide
capital adequacy information to their
home country supervisor before they
report it on the FR Y–7Q. Commenters
stated that modifying home country
reporting frameworks to file the
information on an accelerated timetable
based on the FR Y–7Q would require
significant resources.
In response to the comments received,
the Board has modified the proposal to
stagger implementation filing deadlines.
The modified proposal would be
implemented in two phases. Under
phase one, effective as of December 31,
VerDate Sep<11>2014
17:35 Dec 08, 2023
Jkt 262001
2023, all FR Y–7Q filers that file the FR
Y–15 would report no later than 70 days
after the report date. The remaining
filers would have 90 days to file the FR
Y–7Q after calendar end. Under phase
two, effective as of December 31, 2024,
all remaining FR Y–7Q filers would
report no later than 70 days after the
report date. Moving this implementation
date to December 31, 2024, from the
originally proposed December 31, 2022,
would allow additional time for
respondents to implement the necessary
system enhancements. Further, fiscal
filers with a report date after the
calendar quarter-end periods (e.g.
January 31, April 30, July 31 and
October 31) inherently have additional
time to submit the FR Y–7Q.
Board of Governors of the Federal Reserve
System, December 5, 2023.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–27055 Filed 12–8–23; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–1385; Docket No. CDC–2024–
0098]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Characteristics
of Cases of Priority Fungal Diseases.
These case report forms (CRFs) collect
information on patient demographics,
underlying conditions, diagnosis,
treatments, healthcare utilization, and
outcomes of patients with
coccidioidomycosis, histoplasmosis,
blastomycosis, Candida auris, triazoleresistant Aspergillus fumigatus infection
or colonization, or antifungal-resistant
dermatophytosis.
SUMMARY:
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
85887
CDC must receive written
comments on or before February 9,
2024.
DATES:
You may submit comments,
identified by Docket No. CDC–2024–
0098 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
ADDRESSES:
E:\FR\FM\11DEN1.SGM
11DEN1
85888
Federal Register / Vol. 88, No. 236 / Monday, December 11, 2023 / Notices
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385, Exp. 3/31/2026)—
Revision—National Center for Emerging
and Zoonotic Infectious Diseases
(NCEZID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Fungal diseases cause substantial
illness, ranging from mild infection to
severe or life-threatening invasive
disease. They also constitute a
considerable financial burden on
patients and healthcare systems.
Awareness of fungal diseases is low,
and data collection has historically been
limited in size, scope, and coordination,
which has hindered our understanding
of these diseases. Detailed
epidemiologic and clinical data are
critical to inform appropriate public
health responses.
We plan to enhance surveillance of
high priority fungal diseases across the
United States to better characterize
factors such as disease burden,
geographic scope, patient risk factors,
health disparities, healthcare utilization,
outcomes, and emerging trends. This
project will serve as a Revision of the
information collections project:
Triazole-resistant Aspergillus fumigatus
Case Report Form (CRF). The Revision
will expand the number of fungal
diseases for which data may be
collected. In addition to triazoleresistant A. fumigatus infections, CRFs
have also been developed for
coccidioidomycosis, histoplasmosis,
blastomycosis, C. auris, and antifungalresistant dermatophytosis. CDC is also
changing the name of this information
collections project from Triazoleresistant Aspergillus fumigatus Case
Report Form to Characteristics of Cases
of Priority Fungal Diseases.
We plan to use standardized CRFs to
collect public health surveillance data
for cases of these diseases regarding
demographics (e.g., age, sex, race/
ethnicity, location of residence),
underlying medical conditions,
diagnosis (e.g., clinical presentation,
laboratory testing), treatments, and
outcomes (e.g., hospitalization, vital
status). The corresponding CRF would
be filled out voluntarily by State and
local health departments and contains a
section for medical chart review and an
optional supplemental interview
(including data on potential
occupational or environmental
exposures) of the patient or their
representative. Findings can help
identify populations at higher risk of
these diseases, detect emerging
epidemiologic trends, and guide
prevention and response efforts. They
can also help better focus public and
healthcare provider outreach, inform
efforts to contain or mitigate spread, and
influence health policy and research on
prevention and treatment.
CDC requests OMB approval for an
estimated 1,138 annual burden hours.
There is no cost to respondents other
than their time to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Characteristics of Patients with Environmentally-derived Triazole-resistant Aspergillus fumigatus.
Characteristics of Patients with Coccidioidomycosis.
Characteristics of Patients with
Histoplasmosis.
Characteristics of Patients with Blastomycosis.
Characteristics of Patients with Candida
auris.
Characteristics of Patients with Antifungal-resistant Dermatophytosis.
15
15
30/60
113
10
25
1
250
10
25
1
250
10
25
1
250
15
20
45/60
225
10
10
30/60
50
........................................................................
....................
........................
....................
1,138
Form name
State and Local Health Departments
State and Local Health Departments
State and Local Health Departments
State and Local Health Departments
State and Local Health Departments
State and Local Health Departments
Total ............................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–27081 Filed 12–8–23; 8:45 am]
[60Day–24–24BJ; Docket No. CDC–2023–
0097]
lotter on DSK11XQN23PROD with NOTICES1
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
VerDate Sep<11>2014
17:35 Dec 08, 2023
Average
burden per
response
(in hours)
Number of
respondents
Type of respondents
Jkt 262001
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
ACTION:
Total
burden
(in hours)
Notice with comment period.
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled DP–23–0002
Healthy Schools Evaluation. The project
SUMMARY:
E:\FR\FM\11DEN1.SGM
11DEN1
]]>Agencies
[Federal Register Volume 88, Number 236 (Monday, December 11, 2023)]
[Notices]
[Pages 85887-85888]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27081]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-1385; Docket No. CDC-2024-0098]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a continuing information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled Characteristics of Cases of Priority Fungal Diseases. These case
report forms (CRFs) collect information on patient demographics,
underlying conditions, diagnosis, treatments, healthcare utilization,
and outcomes of patients with coccidioidomycosis, histoplasmosis,
blastomycosis, Candida auris, triazole-resistant Aspergillus fumigatus
infection or colonization, or antifungal-resistant dermatophytosis.
DATES: CDC must receive written comments on or before February 9, 2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0098 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
[[Page 85888]]
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Cases of Priority Fungal Diseases (OMB Control
No. 0920-1385, Exp. 3/31/2026)--Revision--National Center for Emerging
and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Fungal diseases cause substantial illness, ranging from mild
infection to severe or life-threatening invasive disease. They also
constitute a considerable financial burden on patients and healthcare
systems. Awareness of fungal diseases is low, and data collection has
historically been limited in size, scope, and coordination, which has
hindered our understanding of these diseases. Detailed epidemiologic
and clinical data are critical to inform appropriate public health
responses.
We plan to enhance surveillance of high priority fungal diseases
across the United States to better characterize factors such as disease
burden, geographic scope, patient risk factors, health disparities,
healthcare utilization, outcomes, and emerging trends. This project
will serve as a Revision of the information collections project:
Triazole-resistant Aspergillus fumigatus Case Report Form (CRF). The
Revision will expand the number of fungal diseases for which data may
be collected. In addition to triazole-resistant A. fumigatus
infections, CRFs have also been developed for coccidioidomycosis,
histoplasmosis, blastomycosis, C. auris, and antifungal-resistant
dermatophytosis. CDC is also changing the name of this information
collections project from Triazole-resistant Aspergillus fumigatus Case
Report Form to Characteristics of Cases of Priority Fungal Diseases.
We plan to use standardized CRFs to collect public health
surveillance data for cases of these diseases regarding demographics
(e.g., age, sex, race/ethnicity, location of residence), underlying
medical conditions, diagnosis (e.g., clinical presentation, laboratory
testing), treatments, and outcomes (e.g., hospitalization, vital
status). The corresponding CRF would be filled out voluntarily by State
and local health departments and contains a section for medical chart
review and an optional supplemental interview (including data on
potential occupational or environmental exposures) of the patient or
their representative. Findings can help identify populations at higher
risk of these diseases, detect emerging epidemiologic trends, and guide
prevention and response efforts. They can also help better focus public
and healthcare provider outreach, inform efforts to contain or mitigate
spread, and influence health policy and research on prevention and
treatment.
CDC requests OMB approval for an estimated 1,138 annual burden
hours. There is no cost to respondents other than their time to
participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total
Type of respondents Form name respondents responses per response burden (in
respondent (in hours) hours)
----------------------------------------------------------------------------------------------------------------
State and Local Health Departments. Characteristics of 15 15 30/60 113
Patients with
Environmentally-
derived Triazole-
resistant
Aspergillus
fumigatus.
State and Local Health Departments. Characteristics of 10 25 1 250
Patients with
Coccidioidomycosis.
State and Local Health Departments. Characteristics of 10 25 1 250
Patients with
Histoplasmosis.
State and Local Health Departments. Characteristics of 10 25 1 250
Patients with
Blastomycosis.
State and Local Health Departments. Characteristics of 15 20 45/60 225
Patients with
Candida auris.
State and Local Health Departments. Characteristics of 10 10 30/60 50
Patients with
Antifungal-resistant
Dermatophytosis.
-----------------------------------------------------
Total.......................... ..................... ........... .............. ........... 1,138
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2023-27081 Filed 12-8-23; 8:45 am]
BILLING CODE 4163-18-P
